Avant Diagnostics (AVDX): Early Detection of Ovari
Post# of 104
Posted On: 02/09/2016 4:31:48 PM
Avant Diagnostics (AVDX): Early Detection of Ovarian Cancer Increases Survival Rates by Five Times
The American Cancer Society estimates that in 2016, about 22,280 new cases of ovarian cancer will be diagnosed and 14,240 women will die of ovarian cancer in the U.S. Mortality rates for ovarian cancer have declined only slightly in the forty years since the “War on Cancer” was declared. However, other cancers have shown a much greater reduction in mortality, due to the availability of early detection tests and improved treatments. The Surveillance, Epidemiology and End Results (SEER) Program reported that in 2012 in the U.S. approximately 192,446 women were alive who had been diagnosed with ovarian cancer (including those who had been cured of the disease).
Early detection of cancer is the key to using the medicines available today to battle cancer and give the patient the best chance of beating this horrible disease and getting back to a normal life. Avant Diagnostics, Inc. (OTCQB: AVDX) has undertaken this heroic challenge with its OvaDx Pre-Symptomatic Ovarian Cancer Screening Test.
OvaDx is a sophisticated microarray-based test that measures the activation of the immune system in blood samples in response to early stage ovarian tumor cell development. Upon commercialization, it’s estimated that the market opportunity for OvaDX could be $50 million annually as a diagnostic test for ovarian cancer, and it could expand to over $2 billion if the test were to be approved as a generalized screening and/or monitoring tool.
Some form of cancer has affected almost every family in the U.S. either personally or through a member of their immediate family. The common denominator between cancer and any ailment is that the earlier it is detected, the better your chances of survival. Continual monitoring of treatment coupled with early detection can better the odds significantly and prolong your lifespan. If someone gets tested regularly and detects ovarian cancer early, their five-year survival rate is 93 percent compared to a five-year survival rate of only 18 percent if detected in the later stages.
For more information, visit the company website at www.avantdiagnostics.com
Please see disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.com
The American Cancer Society estimates that in 2016, about 22,280 new cases of ovarian cancer will be diagnosed and 14,240 women will die of ovarian cancer in the U.S. Mortality rates for ovarian cancer have declined only slightly in the forty years since the “War on Cancer” was declared. However, other cancers have shown a much greater reduction in mortality, due to the availability of early detection tests and improved treatments. The Surveillance, Epidemiology and End Results (SEER) Program reported that in 2012 in the U.S. approximately 192,446 women were alive who had been diagnosed with ovarian cancer (including those who had been cured of the disease).
Early detection of cancer is the key to using the medicines available today to battle cancer and give the patient the best chance of beating this horrible disease and getting back to a normal life. Avant Diagnostics, Inc. (OTCQB: AVDX) has undertaken this heroic challenge with its OvaDx Pre-Symptomatic Ovarian Cancer Screening Test.
OvaDx is a sophisticated microarray-based test that measures the activation of the immune system in blood samples in response to early stage ovarian tumor cell development. Upon commercialization, it’s estimated that the market opportunity for OvaDX could be $50 million annually as a diagnostic test for ovarian cancer, and it could expand to over $2 billion if the test were to be approved as a generalized screening and/or monitoring tool.
Some form of cancer has affected almost every family in the U.S. either personally or through a member of their immediate family. The common denominator between cancer and any ailment is that the earlier it is detected, the better your chances of survival. Continual monitoring of treatment coupled with early detection can better the odds significantly and prolong your lifespan. If someone gets tested regularly and detects ovarian cancer early, their five-year survival rate is 93 percent compared to a five-year survival rate of only 18 percent if detected in the later stages.
For more information, visit the company website at www.avantdiagnostics.com
Please see disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.com
(0)
(0)Avant Diagnostics, Inc. (AVDX) Stock Research Links
Scroll down for more posts ▼